Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase MergerCRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that it has commenced an exchange offer (the “Offer”) involving its Series C Non-Convertible Redeemable Preferred Stock (the “Series C Preferred Stock”) identified in the Prospectus/Consent Solicitation/Offer to Exchange (as defined below) in connection with Enzon’s previously announced merger with Viskase Companies, Inc. (“Viskase”).
Enzon and Viskase Announce Amendment to Merger AgreementEnzon and Viskase stockholders will respectively own 45% and 55% of the combined company
Enzon and Viskase Enter into Merger AgreementEnzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company
